Bavarian Nordic Announces Interim Results for the First

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014

KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014. * Financial results for the period were as expected with revenue of DKK 676 million (2013: DKK 875 million) and a net loss of DKK 72 million (2013: net loss of DKK 20 million). * In October, the expected year-end cash preparedness was raised from approximately DKK 600 million to approximately DKK 1,000 million, while expected year-end revenues are maintained at the level of DKK 1,200 million, with a break-even result before interest and tax (EBIT). * Contribution margins on IMVAMUNE smallpox vaccine sales have continued to increase during the third quarter. The overall contribution margin for the full year is still expected to be at the same level as 2013. * In October, the Company entered into a license and a supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (hereinafter referred to as Janssen). Under the terms of the contract, which has a potential value up to US$ 187 million, Bavarian Nordic is targeting to produce and deliver material for the production of more than 1 million doses of vaccine for clinical trials and emergency use in the current Ebola outbreak in West Africa. * Janssen also entered into an exclusive option period to evaluate the MVA-BN vaccine platform for three additional infectious disease targets. * As part of the agreement, the Company completed a direct placement of 1,331,984 new shares of a nominal value of DKK 10 each to Johnson & Johnson Development Corporation at a subscription price of DKK 188.4407 per share, raising gross proceeds of DKK 251 million. After the placement, the Company's share capital amounts to DKK 274,448,470, comprising 27,444,847 shares of a nominal value of DKK 10 each. * In October, the Company announced that contract negotiations on partnering PROSTVAC are ongoing. * In September, the U.S. government exercised an option valued at USD 118 million for the purchase of additional doses of IMVAMUNE to maintain the U.S. Strategic National Stockpile (SNS). * In August, the Company signed two contracts with the Canadian government for the supply of IMVAMUNE for the Public Health Agency and the Canadian Department of National Defence respectively. The contracts including options total more than 500,000 doses. * As expected, Bavarian Nordic's MVA-BN patent in Europe was upheld according to a final decision by the European Patent Office in November in the appeal case where several companies had opposed to the patent. * The PROSPECT Phase 3 study of PROSTVAC® is on track to complete enrollment of 1,200 patients by year-end 2014. * The Board of Directors has today decided to introduce a three year incentive program in January 2015 for all employees in the Bavarian Nordic Group. Paul Chaplin, President & CEO of Bavarian Nordic said: "Over the past few months, we have achieved significant milestones. We were awarded a contract by the U.S. Government to continue deliveries of our IMVAMUNE smallpox vaccine. More importantly, the recent license and supply agreement with Janssen on our Ebola vaccine is a strong acknowledgement of the versatility of our MVA-BN technology and strength of our manufacturing capabilities. We are proud to be working with a global leader in healthcare in response to the current global health crisis. Additionally, the agreement has significantly strengthened our financial position." Selected upcoming milestones * Complete enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study (2014) * Initiate final Phase 3 study of IMVAMUNE (2014) * Complete Phase 2 study of freeze-dried IMVAMUNE to support a pre-EUA submission (2015) * Complete transfer of validated freeze-dried manufacturing process to a commercial scale facility (2015) * Finalize clinical development plan for CV-301 for prioritized indications (2014) * Finalize validation of the PROSTVAC commercial manufacturing process and prepare launch material * Potential IMVANEX/IMVAMUNE orders from rest of world * Submit Investigational New Drug application for MVA-BN RSV followed by initiation of Phase 1 study (2015) * Initiation of  Phase 1 study of a prime-boost Ebola vaccine regimen consisting of MVA-BN Filo and Janssen's Advac® vaccine (2015) * Manufacture and deliver MVA-BN Filo vaccine to Janssen (targeting more than 1 million doses to contribute to the prime-boost regimen) (2015) Financials +-----------------+-----------+-----------+-----------+-----------+ |  | 9m 2014| 9m 2013| 9m 2014| 9m 2013| | |DKK million|DKK million|USD million|USD million| +-----------------+-----------+-----------+-----------+-----------+ |Revenue | 676| 875| 117| 151| +-----------------+-----------+-----------+-----------+-----------+ |EBIT | (121)| (6)| (21)| (1)| +-----------------+-----------+-----------+-----------+-----------+ |Cash preparedness| 356| 546| 61| 94| +-----------------+-----------+-----------+-----------+-----------+ Danish kroner (DKK) is the Company's functional currency. All USD figures provided above are based upon a USD/DKK exchange rate of 5.8. As previously communicated, a significant part of the planned IMVAMUNE deliveries to the SNS will take place in the fourth quarter and thus revenues are back-end loaded. For the full year, Bavarian Nordic expects to deliver approximately 6.5 million doses. Hence, the 2014 full-year expectations are maintained with revenues in the level of DKK 1,200 million and a break-even result before interest and tax (EBIT). The Infectious Diseases division is expected to generate an EBIT of approximately DKK 400 million, which will be offset by total costs of DKK 400 million in the Cancer Immunotherapy division, primarily relating to the global Phase 3 study of PROSTVAC®. After signing the license and supply agreement with Janssen in October, the Company raised its expectations for the year-end cash preparedness from approximately DKK 600 million to DKK 1,000 million including a reduction in debt and credit facilities of approximately DKK 150 million. Group key figures are found at the end of this announcement. The full financial statements for the period can be downloaded from the Company's website: www.bavarian-nordic.com along with a spreadsheet containing selected accounting figures. Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654 Conference call and webcast The management of Bavarian Nordic will host a conference call today at 2 pm CET (8 am EST) to present the interim results followed by a Q&A session. Dial-in numbers for the conference call are: Denmark: +45 32 72 80 18, UK: +44 (0) 844 571 8957, USA: +1 866 682 8490. A live and archived webcast of the call and relevant slides will be available at http://www.bavarian- nordic.com/investor/events.aspx?event=2874. About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in Canada and in the European Union where it is marketed under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the U.S. (OTC) under the symbol BVNRY.  For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Group Key Figures DKK million 9m 2014 9m 2013 FY 2013 -------------------------------------------------------------------------------   un-audited un-audited audited Income statements Revenue   675,6   875,0   1.212,5 Production costs   328,1   346,8   484,7 Research and development costs   313,5   385,0   496,6 Distribution costs   34,3   27,4   40,8 Administrative costs   121,0   121,8   157,0 Income before interest and taxes (EBIT)   (121,3)   (6,0)   33,4 Financial items, net   36,8   (11,7)   (27,2) Income before company tax   (84,5)   (17,7)   6,2 Net profit for the period   (72,0)   (19,9)   (46,7) Balance sheet Total non-current assets   592,5   585,7   551,8 Total current assets   671,3   868,7   900,4 Total assets   1.263,8   1.454,4   1.452,2 Equity   881,5   996,6   976,3 Non-current liabilities   90,0   93,9   86,7 Current liabilities   292,3   363,9   389,2 Cash flow statements Securities, cash and cash equivalents   236,1   426,0   532,1 Cash flow from operating activities   (209,7)   0,8   147,1 Cash flow from investment activities   13,0   (200,4)   (146,5)  - Investment in intangible assets   (43,3)   (87,0)   (111,0)  - Investment in property, plant and equipment   (39,7)   (28,5)   (44,4) Cash flow from financing activities   (4,3)   (5,0)   (7,1) Financial Ratios (DKK) (1)) Earnings (basic) per share of DKK 10(2))   (2,8)   (0,8)   (1,8) Net asset value per share   33,7   38,2   37,4 Share price at period-end   114   66   89 Share price/Net asset value per share   3,4   1,7   2,4 Number of outstanding shares at period-end   26.131   26.094   26.094 Equity share 70% 69% 67% Number of employees, converted to full-time,   415   427   426 at period-end ------------------------------------------------------------------------------- 1) Earnings per share (EPS) is calculated in accordance with IAS 33 "Earning per share". The financial ratios have been calculated in accordance with "Anbefalinger og Nøgletal 2010" (Recommendations and Financial ratios 2010). 2) Due to issue of new shares (exercise of warrants) in May 2014, earnings per share for 2013 has been calculated based on the average number of shares for 2014 in accordance with IFRS 33.64. [HUG#1870760]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading